메뉴 건너뛰기




Volumn 173, Issue 4, 2015, Pages 930-939

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TILDRAKIZUMAB; DERMATOLOGICAL AGENT; INTERLEUKIN 23P19; MONOCLONAL ANTIBODY;

EID: 84945443119     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13932     Document Type: Article
Times cited : (233)

References (25)
  • 1
    • 0035069606 scopus 로고    scopus 로고
    • The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey
    • Krueger G, Koo J, Lebwohl M, et al,. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
    • (2001) Arch Dermatol , vol.137 , pp. 280-284
    • Krueger, G.1    Koo, J.2    Lebwohl, M.3
  • 2
    • 70350343375 scopus 로고    scopus 로고
    • Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis
    • Bansback N, Sizto S, Sun H, et al,. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-18.
    • (2009) Dermatology , vol.219 , pp. 209-218
    • Bansback, N.1    Sizto, S.2    Sun, H.3
  • 3
    • 24944542391 scopus 로고    scopus 로고
    • Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey
    • Nijsten T, Margolis DJ, Feldman SR, et al,. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005; 52: 434-44.
    • (2005) J Am Acad Dermatol , vol.52 , pp. 434-444
    • Nijsten, T.1    Margolis, D.J.2    Feldman, S.R.3
  • 4
    • 1842555395 scopus 로고    scopus 로고
    • Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
    • Stern RS, Nijsten T, Feldman SR, et al,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
    • (2004) J Investig Dermatol Symp Proc , vol.9 , pp. 136-139
    • Stern, R.S.1    Nijsten, T.2    Feldman, S.R.3
  • 5
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
    • (2008) Lancet , vol.371 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3
  • 6
    • 43449139402 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    • Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
    • (2008) Lancet , vol.371 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3
  • 7
    • 84900485940 scopus 로고    scopus 로고
    • Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: Results from a randomized phase III study
    • Papp KA, Sundaram M, Bao Y, et al,. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol 2013; 28: 790-8.
    • (2013) J Eur Acad Dermatol Venereol , vol.28 , pp. 790-798
    • Papp, K.A.1    Sundaram, M.2    Bao, Y.3
  • 8
    • 84855938590 scopus 로고    scopus 로고
    • A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis
    • Gordon KB, Langley RG, Gottlieb AB, et al,. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132: 304-14.
    • (2012) J Invest Dermatol , vol.132 , pp. 304-314
    • Gordon, K.B.1    Langley, R.G.2    Gottlieb, A.B.3
  • 9
    • 33751546237 scopus 로고    scopus 로고
    • IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
    • Chan JR, Blumenschein W, Murphy E, et al,. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-87.
    • (2006) J Exp Med , vol.203 , pp. 2577-2587
    • Chan, J.R.1    Blumenschein, W.2    Murphy, E.3
  • 10
    • 59149106117 scopus 로고    scopus 로고
    • Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways
    • Nair RP, Duffin KC, Helms C, et al,. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199-204.
    • (2009) Nat Genet , vol.41 , pp. 199-204
    • Nair, R.P.1    Duffin, K.C.2    Helms, C.3
  • 11
    • 84929359284 scopus 로고    scopus 로고
    • Clinical improvement in psoriasis with specific targeting of interleukin (IL)-23
    • Kopp T, Riedl E, Bangert C, et al,. Clinical improvement in psoriasis with specific targeting of interleukin (IL)-23. Nature 2015; 521: 222-6.
    • (2015) Nature , vol.521 , pp. 222-226
    • Kopp, T.1    Riedl, E.2    Bangert, C.3
  • 12
    • 84897146802 scopus 로고    scopus 로고
    • Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
    • Sofen H, Smith S, Matheson RT, et al,. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032-40.
    • (2014) J Allergy Clin Immunol , vol.133 , pp. 1032-1040
    • Sofen, H.1    Smith, S.2    Matheson, R.T.3
  • 13
    • 0037313578 scopus 로고    scopus 로고
    • Interleukin-12 and the regulation of innate resistance and adaptive immunity
    • Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
    • (2003) Nat Rev Immunol , vol.3 , pp. 133-146
    • Trinchieri, G.1
  • 14
    • 34548133583 scopus 로고    scopus 로고
    • Development, cytokine profile and function of human interleukin 17-producing helper T cells
    • Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
    • (2007) Nat Immunol , vol.8 , pp. 950-957
    • Wilson, N.J.1    Boniface, K.2    Chan, J.R.3
  • 15
    • 77958072084 scopus 로고    scopus 로고
    • Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
    • Hueber W, Patel DD, Dryja T, et al,. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
    • (2010) Sci Transl Med , vol.2 , pp. 52ra72
    • Hueber, W.1    Patel, D.D.2    Dryja, T.3
  • 16
    • 84862860846 scopus 로고    scopus 로고
    • IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
    • Krueger JG, Fretzin S, Suarez-Farinas M, et al,. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145-54.
    • (2012) J Allergy Clin Immunol , vol.130 , pp. 145-154
    • Krueger, J.G.1    Fretzin, S.2    Suarez-Farinas, M.3
  • 17
    • 78650706586 scopus 로고    scopus 로고
    • Cutting edge: A critical functional role for IL-23 in psoriasis
    • Tonel G, Conrad C, Laggner U, et al,. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010; 185: 5688-91.
    • (2010) J Immunol , vol.185 , pp. 5688-5691
    • Tonel, G.1    Conrad, C.2    Laggner, U.3
  • 18
    • 33750450544 scopus 로고    scopus 로고
    • Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection
    • Chackerian AA, Chen SJ, Brodie SJ, et al,. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006; 74: 6092-9.
    • (2006) Infect Immun , vol.74 , pp. 6092-6099
    • Chackerian, A.A.1    Chen, S.J.2    Brodie, S.J.3
  • 19
    • 78149491862 scopus 로고    scopus 로고
    • IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans
    • Kagami S, Rizzo HL, Kurtz SE, et al,. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010; 185: 5453-62.
    • (2010) J Immunol , vol.185 , pp. 5453-5462
    • Kagami, S.1    Rizzo, H.L.2    Kurtz, S.E.3
  • 20
    • 71849109959 scopus 로고    scopus 로고
    • Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17
    • Schulz SM, Kohler G, Schutze N, et al,. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol 2008; 181: 7891-901.
    • (2008) J Immunol , vol.181 , pp. 7891-7901
    • Schulz, S.M.1    Kohler, G.2    Schutze, N.3
  • 21
    • 84865116628 scopus 로고    scopus 로고
    • Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state
    • Teng MW, Vesely MD, Duret H, et al,. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72: 3987-96.
    • (2012) Cancer Res , vol.72 , pp. 3987-3996
    • Teng, M.W.1    Vesely, M.D.2    Duret, H.3
  • 22
    • 84868613705 scopus 로고    scopus 로고
    • Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
    • Grivennikov SI, Wang K, Mucida D, et al,. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8.
    • (2012) Nature , vol.491 , pp. 254-258
    • Grivennikov, S.I.1    Wang, K.2    Mucida, D.3
  • 23
    • 84859736230 scopus 로고    scopus 로고
    • IL-12 and IL-23 affect photocarcinogenesis differently
    • Jantschitsch C, Weichenthal M, Proksch E, et al,. IL-12 and IL-23 affect photocarcinogenesis differently. J Invest Dermatol 2012; 132: 1479-86.
    • (2012) J Invest Dermatol , vol.132 , pp. 1479-1486
    • Jantschitsch, C.1    Weichenthal, M.2    Proksch, E.3
  • 24
    • 33746534417 scopus 로고    scopus 로고
    • IL-23 promotes tumour incidence and growth
    • Langowski JL, Zhang X, Wu L, et al,. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
    • (2006) Nature , vol.442 , pp. 461-465
    • Langowski, J.L.1    Zhang, X.2    Wu, L.3
  • 25
    • 33645519047 scopus 로고    scopus 로고
    • Enhanced photocarcinogenesis in interleukin-12-deficient mice
    • Maeda A, Schneider SW, Kojima M, et al,. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006; 66: 2962-9.
    • (2006) Cancer Res , vol.66 , pp. 2962-2969
    • Maeda, A.1    Schneider, S.W.2    Kojima, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.